Skip to content
10-Q

Quarterly Report

REGENEREX PHARMA, INC. RGPX

0001472375-25-000140

← back to feed
Filed
Nov 17, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Nov 17, 2025 282.37M sh
Operating Cash Flow Q2 2025 · Sep 30, 2025 −$997.3K
Operating Cash Flow Q2 2025 · Sep 30, 2024 −$181.94K
Cash And Equivalents Q2 2025 · Sep 30, 2025 $11.66K
Cash And Equivalents Q2 2025 · Mar 31, 2025 $653.03K
Stockholders Equity Q2 2025 · Sep 30, 2025 −$4.7M
Stockholders Equity Q2 2025 · Jun 30, 2025 −$4.55M
Stockholders Equity Q2 2025 · Mar 31, 2025 −$4.16M
Stockholders Equity Q2 2025 · Sep 30, 2024 −$4.76M
Stockholders Equity Q2 2025 · Jun 30, 2024 −$4.31M
Stockholders Equity Q2 2025 · Mar 31, 2024 −$4.06M
Current Liabilities Q2 2025 · Sep 30, 2025 $4.92M
Current Liabilities Q2 2025 · Mar 31, 2025 $4.92M
Total Liabilities Q2 2025 · Sep 30, 2025 $5.32M
Total Liabilities Q2 2025 · Mar 31, 2025 $5.42M
Current Assets Q2 2025 · Sep 30, 2025 $48.43K
Current Assets Q2 2025 · Mar 31, 2025 $653.38K
Total Assets Q2 2025 · Sep 30, 2025 $617.76K
Total Assets Q2 2025 · Mar 31, 2025 $1.26M
Rd Expense Q2 2025 · Sep 30, 2025 $136.43K
Rd Expense Q2 2025 · Sep 30, 2025 $133.51K
Net Income Q2 2025 · Sep 30, 2025 −$814.01K
Net Income Q2 2025 · Sep 30, 2025 −$1.48M
Net Income Q2 2025 · Jun 30, 2025 −$663.58K
Net Income Q2 2025 · Sep 30, 2024 −$529.57K
Net Income Q2 2025 · Sep 30, 2024 −$802.13K
Net Income Q2 2025 · Jun 30, 2024 −$272.56K
Operating Income Q2 2025 · Sep 30, 2025 −$786.71K
Operating Income Q2 2025 · Sep 30, 2025 −$1.42M
Operating Income Q2 2025 · Sep 30, 2024 −$258.38K
Operating Income Q2 2025 · Sep 30, 2024 −$512.66K